Mexico has published NOM-137-SSA1-2025, a major overhaul of its medical device labeling standard that introduces stricter traceability requirements, expanded use of international symbols, and stronger sterility labeling expectations. Foreign manufacturers and importers will feel the greatest impact, with likely updates needed across labels, IFUs, and contra-labeling processes. With mandatory compliance kicking in on May 14, 2027, the roughly 360-day transition window makes now the right time to start your gap assessment.
Mexico has officially published NOM-137-SSA1-2025, replacing the previous NOM-137-SSA1-2008 medical device labeling standard. The updated regulation modernizes labeling requirements for medical devices in Mexico, with stronger focus on traceability, sterile product labeling, safety information, and post-market surveillance alignment.
The new standard also moves Mexico closer to international regulatory practices by incorporating harmonized symbols, clearer import labeling requirements, and broader lifecycle safety expectations. While the NOM is applicable from publication, mandatory compliance becomes effective on May 14, 2027.
The previous 2008 version focused largely on basic labeling content requirements. The 2025 revision goes significantly further by emphasizing:
The regulation also aligns more closely with modern international regulatory principles commonly seen in frameworks such as ISO 13485, IMDRF concepts, and global post-market surveillance expectations.
1. Traceability Takes Center Stage
One of the most notable additions is the explicit inclusion of traceability requirements within medical device labeling. The regulation now emphasizes identification elements such as:
The standard also permits electronic support tools such as QR codes, RFID, and barcodes to supplement labeling information.
While Mexico has not formally implemented a UDI system equivalent to the EU MDR or FDA UDI framework, this change strongly suggests future movement toward enhanced device traceability infrastructure.
For manufacturers, this means now is the ideal time to evaluate:
2. Greater Use of International Symbols
The updated NOM expands the acceptance and structure around internationally harmonized labeling symbols. Manufacturers may now rely more heavily on standardized symbols, provided risks related to user comprehension are appropriately evaluated.
This shift creates opportunities to:
However, companies should expect:
Manufacturers using legacy text-heavy labels may need substantial updates to maintain compliance.
3. Enhanced Requirements for Sterile Devices
Sterile devices are expected to experience the greatest regulatory impact under the new NOM.
The standard introduces stronger expectations regarding:
Packaging systems and Instructions for Use (IFUs) will likely require revision to ensure all required sterility information is appropriately communicated.
This is especially significant for:
Manufacturers should anticipate increased scrutiny during:
4. Stronger Rules for Contra-Labels and Imported Products
The updated regulation clarifies requirements for Mexican counter-labeling (“contra-etiquetas”), which are commonly used for imported devices.
This change could significantly affect:
Companies relying heavily on local Mexican relabeling processes should carefully reassess:
Operationally, this may require tighter coordination between global regulatory, quality, and supply chain teams.
5. Labeling Is Now More Closely Linked to Post-Market Surveillance
Perhaps the most strategic change is the stronger integration between labeling compliance and lifecycle safety management.
The new NOM explicitly connects labeling controls with:
This reflects a global regulatory trend toward treating labeling as a living component of device safety rather than a static market authorization requirement.
Manufacturers should expect COFEPRIS to increasingly evaluate consistency between:
Label and IFU Updates
Manufacturers will likely need to revise:
Regulators will likely expect tighter alignment across:
Inconsistencies that may have historically gone unnoticed could now attract regulatory attention.
Foreign manufacturers using Mexican distributors or importers may face operational changes regarding:
Sterile devices will likely become a focal point for inspections and registration assessments due to enhanced sterility-related labeling requirements.
Labeling is increasingly viewed as part of the overall product lifecycle management system, reinforcing the importance of:
According to the published standard:
The regulation also includes provisions allowing companies additional time to exhaust existing packaging inventory under certain conditions.
To prepare for compliance, companies should begin:
Gap Assessments
Review current Mexican labeling against new NOM-137-SSA1-2025 requirements.
IFU and Artwork Reviews
Evaluate:
Distributor and Importer Alignment
Clarify ownership of:
QMS Integration
Ensure labeling controls align with:
Sterile Product Risk Review
Conduct targeted reviews for:
NOM-137-SSA1-2025 represents one of the most significant updates to Mexico’s medical device regulatory framework in years. While many changes align Mexico more closely with international expectations, the operational impact for manufacturers—particularly foreign companies—could be substantial.
Organizations that begin remediation activities early will be better positioned to:
For global manufacturers, this update is more than a labeling change—it is a signal that Mexico continues moving toward a more mature, integrated, and internationally harmonized medical device regulatory environment.
For the official text, please refer to the DOF publication.
Learn more about:
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us